Any current/future new fundraising through debt or equity?

There is no specific mention of any new fundraising through debt or equity in the transcript. The company emphasizes disciplined capital execution with no blockbuster capex planned in the next 2-3 years. Future capex will be medium-scale projects focused on quick turnaround and significant returns using existing infrastructure. The focus remains on managing the balance sheet prudently, with no indication of immediate or planned large-scale fundraising. Debt-to-EBITDA may have already peaked, and the company expects improvement going forward. Finance costs may increase modestly due to new proje

Any current/future capex/capital investment/strategic investment?

Ongoing Zone 4 expansion project with new capacities coming online over next few quarters. New multipurpose plant (MPP) at Zone 4 to be commissioned in Q4 FY26, enhancing product development flexibility. Calcium Chloride facility commissioning expected in the current quarter at Zone 4. New 4,000 TPA PEDA project at Zone 4 (Jhagadia) utilizing Ethylation raw materials, targeting agrochemical industry demand. Strategic partnership with DCM Shriram for long-term chlorine supply to Zone 4 downstream chemicals facility. Debottlenecking initiatives on MMA capacity to scale up volumes furth

Future growth expectations in sales/revenue/volumes?

The company expects steady volume growth supported by capacity expansions and debottlenecking initiatives, particularly in MMA, with incremental capacity coming online from Q4 FY26 and through FY27. Market expansion efforts continue globally, especially in Europe, Middle East, and Africa, alongside recovery in U.S. volumes as tariff issues are addressed. Medium-scale, innovation-led capex projects over the next 2-3 years are aimed at quick turnaround and significant return generation. The company anticipates gradual recovery in volumes in agrochemicals and other specialty chemicals segme

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects medium-term volume visibility to remain healthy across most businesses despite near-term uncertainties (Page 3). EBITDA aspirations for FY28 remain a firm commitment, supported by volume ramp-up, cost optimization, and monetization of ongoing capex projects (Page 3). Incremental capacity additions such as the multipurpose plant, calcium chloride facility, and PEDA project will drive profitable growth and volume ramp-up in the next 12-18 months (Pages 5, 6). Operating leverage is a key driver of margin improvement, expected to support EBITDA growth as volumes increase (Page

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders for Aarti Industries. However, management indicated they have active conversations and decent relationships with customers for upcoming projects such as multipurpose plant and PEDA. They clarified that none of the upcoming projects have take-or-pay contracts, implying orders are not fully secured with firm commitments. Confidence in volume placement exists, supported by ongoing customer engagement. The company is commissioning several projects sequentially, suggesting a healthy pipeline but without

IN US

Sale is live|00:00:00left today

Aarti Industries LtdQ3 FY25Chemicals & Petrochemicals

Aarti Industries Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹457P/E: 41.0Market Cap: ₹16.9K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→The company expects steady volume growth supported by capacity expansions and debottlenecking initiatives, particularly in MMA, with incremental capacity coming online from Q4 FY26 and through FY27.
→Market expansion efforts continue globally, especially in Europe, Middle East, and Africa, alongside recovery in U.S. volumes as tariff issues are addressed.
→Medium-scale, innovation-led capex projects over the next 2-3 years are aimed at quick turnaround and significant return generation.
→The company anticipates gradual recovery in volumes in agrochemicals and other specialty chemicals segments as trade and margin pressures ease.
→Volume sustainability at current levels is expected to drive operating leverage, supporting margin and revenue growth.
→Long-term volume visibility remains healthy across most businesses despite near-term uncertainties.
→Overall revenue growth is driven by proactive market diversification, increased global footprint, and ongoing capacity additions.

Margin guidance

Category 3

→The company expects medium-term volume visibility to remain healthy across most businesses despite near-term uncertainties (Page 3).
→EBITDA aspirations for FY28 remain a firm commitment, supported by volume ramp-up, cost optimization, and monetization of ongoing capex projects (Page 3).
→Incremental capacity additions such as the multipurpose plant, calcium chloride facility, and PEDA project will drive profitable growth and volume ramp-up in the next 12-18 months (Pages 5, 6).
→Operating leverage is a key driver of margin improvement, expected to support EBITDA growth as volumes increase (Page 6).
→Cost-cutting initiatives totaling INR150-200 crore are underway, with 40-50% of benefits yet to flow through, indicating further profit improvement potential (Page 13).
→Management aims for disciplined capital expenditure focusing on medium-scale projects with fast turnaround and significant returns, avoiding large-ticket capex for the next 2-3 years (Pages 5, 7).
→The balance sheet debt-to-EBITDA ratio may have peaked, with expectations of improvement going forward, supporting financial stability (Page 20).

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no specific mention of any new fundraising through debt or equity in the transcript.
→The company emphasizes disciplined capital execution with no blockbuster capex planned in the next 2-3 years.
→Future capex will be medium-scale projects focused on quick turnaround and significant returns using existing infrastructure.
→The focus remains on managing the balance sheet prudently, with no indication of immediate or planned large-scale fundraising.
→Debt-to-EBITDA may have already peaked, and the company expects improvement going forward.
→Finance costs may increase modestly due to new projects, but interest rate softening is anticipated to help manage costs.
→Overall, the company aims to maintain a stable debt profile and manage leverage amid ongoing capex and innovation-led growth.

Order book

→The transcript does not explicitly mention the current or expected order book or pending orders for Aarti Industries.
→However, management indicated they have active conversations and decent relationships with customers for upcoming projects such as multipurpose plant and PEDA.
→They clarified that none of the upcoming projects have take-or-pay contracts, implying orders are not fully secured with firm commitments.
→Confidence in volume placement exists, supported by ongoing customer engagement.
→The company is commissioning several projects sequentially, suggesting a healthy pipeline but without specific orderbook data disclosed.
→Overall, long-term volume visibility remains healthy across most businesses despite near-term uncertainties.

Capex plans

Yes

→Ongoing Zone 4 expansion project with new capacities coming online over next few quarters.
→New multipurpose plant (MPP) at Zone 4 to be commissioned in Q4 FY26, enhancing product development flexibility.
→Calcium Chloride facility commissioning expected in the current quarter at Zone 4.
→New 4,000 TPA PEDA project at Zone 4 (Jhagadia) utilizing Ethylation raw materials, targeting agrochemical industry demand.
→Strategic partnership with DCM Shriram for long-term chlorine supply to Zone 4 downstream chemicals facility.
→Debottlenecking initiatives on MMA capacity to scale up volumes further from Q4 FY26.
→Capex for FY26 expected around INR 1,000 crore; FY27 capex to be substantially lower.
→Future capex focus on medium-ticket size projects utilizing existing infrastructure for faster turnaround and returns.
→Emphasis shifting towards innovation-led growth and value-added chemistry as current capex cycle concludes.

How does Aarti Industries Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Aarti Industries Ltd

Rev 3Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Aarti Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio